Literature DB >> 31183784

Conversion of AspireAssist System® to Sleeve Gastrectomy: Technical Video Description.

Ramon Vilallonga1,2, Refik Bademci3, Renato Roriz-Silva4, Sergi Sanchez-Cordero5, Yuhamy Curbelo6, Ariel Almanza7.   

Abstract

PURPOSE: The AspireAssist System® (Aspire Bariatrics, Inc. King of Prussia, PA) is a new endoscopic procedure used to treat obese patients. The aim of this dedicated video is to present a case that required revision surgery due to failure of the AspireAssist System®, and to show how the cannula was removed from the abdomen, and why sleeve gastrectomy (SG) was a good option for revisional surgery in that patient. We aim to discuss technical aspects. PATIENT AND METHODS: A 43-year-old female patient who underwent a placement in 2016. Her initial BMI (body mass index) was 38 kg/m2, with a follow-up period of 26 months. A revisional surgery was performed including dissection of the previous gastric fistula and adhesiolysis from the previous AspireAssist System® placement. A complete dissection of the gastrostomy, including removal of all the system, was done. A decision was made, once the incisura angularis and the placement of a 40 Fch bougie showed that the transection could be performed. SG was done. Patients showed an uneventful postoperative course and 4 months follow-up with 45% EWL.
CONCLUSION: In case of having the device in place, the surgeon must be aware to remove intraoperatively or endoscopically, the device. Surgeons should consider endoscopic removal of the AspireAssist System® before conversion to another procedure (SG or GBP) at least 6 months of the removal. Removal of the AspireAssist System® should be performed endoscopically but direct conversion to another bariatric procedure can be considered, either to SG or GBP depending on the technical intraoperative aspects.

Entities:  

Keywords:  AspireAssist System®; Conversion; Failure; Laparoscopic revisional surgery; Sleeve gastrectomy; Weight regain

Mesh:

Year:  2019        PMID: 31183784     DOI: 10.1007/s11695-019-03993-3

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  6 in total

Review 1.  Aspiration Therapy for Obesity.

Authors:  Shelby Sullivan
Journal:  Gastrointest Endosc Clin N Am       Date:  2017-04

2.  The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes.

Authors:  Gontrand López-Nava; Inmaculada Bautista-Castaño; Amaya Jimenez; Teresa de Grado; Juan Pedro Fernandez-Corbelle
Journal:  Surg Obes Relat Dis       Date:  2014-10-07       Impact factor: 4.734

3.  Aspiration therapy for obesity; a safe and effective treatment.

Authors:  Erik Norén; Henrik Forssell
Journal:  BMC Obes       Date:  2016-12-28

Review 4.  The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy.

Authors:  Nitin Kumar; Shelby Sullivan; Christopher C Thompson
Journal:  Diabetes Metab Syndr Obes       Date:  2017-07-06       Impact factor: 3.168

5.  Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial.

Authors:  Christopher C Thompson; Barham K Abu Dayyeh; Robert Kushner; Shelby Sullivan; Alan B Schorr; Anastassia Amaro; Caroline M Apovian; Terrence Fullum; Amir Zarrinpar; Michael D Jensen; Adam C Stein; Steven Edmundowicz; Michel Kahaleh; Marvin Ryou; J Matthew Bohning; Gregory Ginsberg; Christopher Huang; Daniel D Tran; Joseph P Glaser; John A Martin; David L Jaffe; Francis A Farraye; Samuel B Ho; Nitin Kumar; Donna Harakal; Meredith Young; Catherine E Thomas; Alpana P Shukla; Michele B Ryan; Miki Haas; Heidi Goldsmith; Jennifer McCrea; Louis J Aronne
Journal:  Am J Gastroenterol       Date:  2016-12-06       Impact factor: 10.864

6.  Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study.

Authors:  Max Nyström; Evzen Machytka; Erik Norén; Pier Alberto Testoni; Ignace Janssen; Jesus Turró Homedes; Jorge Carlos Espinos Perez; Roman Turro Arau
Journal:  Obes Surg       Date:  2018-07       Impact factor: 4.129

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.